Qiagen Acquires UK's DxS in Deal Worth up to $130M

Qiagen said that the acquisition, along with the fact that it has more than 15 companion diagnostic collaborations with pharma companies, provides it with a leading position in the personalized healthcare market.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.